<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2285">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131412</url>
  </required_header>
  <id_info>
    <org_study_id>GWCMC_HJ_XY_001</org_study_id>
    <nct_id>NCT05131412</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells for the Treatment of Pneumonia Post Haematopoietic Stem Cell Transplantation</brief_title>
  <acronym>MSCTPHSCT</acronym>
  <official_title>Mesenchymal Stem Cells for the Treatment of Pneumonia Post Haematopoietic Stem Cell Transplantation: a a Retrospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Women and Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Women and Children's Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether mesenchymal stromal cell (MSC) treatment&#xD;
      contribute to the good prognosis in patients with transplant-related complication, pneumonia&#xD;
      post hematopoietic stem cell transplantation (HSCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hematopoietic stem cell transplantation (HSCT) is a standard therapy strategy for most&#xD;
      hematologic disorders and malignancies. Despite the improved survival attributed to advances&#xD;
      in HSCT including transplantation techniques and supportive care, transplant-related&#xD;
      pneumonia (severe pneumonia in particular) remains the leading cause of death for most HSCT&#xD;
      patients and a major challenge for clinicians.&#xD;
&#xD;
      Mesenchymal stromal cells (MSCs), a form of multipotent cells, have been applied in therapy&#xD;
      for various intractable disorders. MSC exerts its therapeutic effect through various&#xD;
      biological functions including immunoregulation, tissue repairing, self-renew and&#xD;
      differentiating into various cell lines. The American Thoracic Society has also suggested&#xD;
      MSCs as a cell therapy agent for lung diseases. However, MSC therapy for pneumonia following&#xD;
      HSCT has not been well investigated.&#xD;
&#xD;
      By investigating the efficacy of MSC treatment for HSCT-related pneumonia via comparing the&#xD;
      outcomes in patients with and without MSC treatment, this study will provide a promising&#xD;
      therapy for HSCT-related pneumonia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2018</start_date>
  <completion_date type="Actual">October 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overall cure rate</measure>
    <time_frame>12 months</time_frame>
    <description>the proportion of cured cases in all cases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time to cure</measure>
    <time_frame>12 months</time_frame>
    <description>the time from the first diagnosis of pneumonia to a cure was achieved</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">107</enrollment>
  <condition>Pneumonia</condition>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>mesenchymal stromal cell</arm_group_label>
    <description>Patients treated with mesenchymal stromal cell</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-mesenchymal stromal cell</arm_group_label>
    <description>Patients treated without mesenchymal stromal cell</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent hematopoietic stem cell transplantation (HSCT) in Guangzhou Women&#xD;
        and Children's Medical Center and got pneumonia after HSCT.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with pneumonia after HSCT;&#xD;
&#xD;
          -  patients under the age of 18 years;&#xD;
&#xD;
          -  patients with normal pulmonary function before HSCT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with other severe complications in progress when pneumonia occurred.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Jiang</last_name>
    <role>Study Director</role>
    <affiliation>Guangzhou Women and Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou Women and Children's Medical Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510623</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Women and Children's Medical Center</investigator_affiliation>
    <investigator_full_name>Xu Yang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal Stromal Cell</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

